Floatz logo

Ale.P02

Cervical Squamous Cell Carcinoma

Alentis Therapeutics AGPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Cervical Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Rigosertib
Traws Pharma, Inc.
Phase 2B

View all 32 →

Same molecule, other indications

Ale.P02 is also rated in:

squamous cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
esophageal squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →